Purpose: This was an evidence-based study to assess which creatinine-based equation was most useful for estimated glomerular filtration rate (eGFR) in Chinese adults with chronic kidney disease (CKD).
Methods: Multiple databases were searched to collect relevant studies on creatinine-based eGFR equations for Chinese adults with CKD in Chinese and English from January 2009 to January 2023, using "glomerular filtration rate", "GFR equations", "Chinese CKD", "chronic kidney disease", "equation development" and "equation validation". The quality of each study was assessed using the diagnostic test accuracy review by RevMan 5.4 software. The equation name, study publication year, first author, reference method for eGFR, CKD numbers, age (age ranges) of individuals, mGFR value, bias, precision, and 30% accuracy (P) of each included equation were recorded accordingly by 2 independent investigators.
Results: Of the 838 studies identified, 23 studies based on 6 creatinine-based GFR equations were included in the present review, ie, the CKD-EPI, Asian modified CKD-EPI, FAS, EKFC, Xiangya, and BSI1 equations. A total of 2979 CKD patients were included for FAS equation external assessment, and the total P was 72.6 %; 970 CKD patients for the EKFC equation, and the total P was 73.1 %. 1778 CKD patients (≥60 years of age) with a mean eGFR from 39.7 to 47.6 mL/min/1.73 m were pooled to assess the prediction accuracy of the BSI1 equation and demonstrated that the bias was small (-3.8-3.5 mL/min/1.73 m), the precision was excellent (10.2-16.8 mL/min/1.73 m), and the total P was 69.6 %.
Conclusions: Currently, the FAS and EKFC equations have higher P for eGFR among Chinese adult CKD patients. The bias and precision of BSI1 formulas was acceptable for eGFR in elderly ≥ 60 years of age, while the P was relatively low. Therefore, there is a clinical need to develop more accurate equations for eGFR in older CKD adults. While promising, these findings require further validation in large well controlled clinical studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cca.2025.120124 | DOI Listing |
Curr Cardiol Rev
January 2025
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, 342005, India.
Cardiovascular-kidney-metabolic (CKM) syndrome is the association between obesity, diabetes, CKD (chronic kidney disease), and cardiovascular disease. GDF-15 mainly acts through the GFRAL (Glial cell line-derived neurotrophic factor Family Receptor Alpha-Like) receptor. GDF-15 and GDFRAL complex act mainly through RET co-receptors, further activating Ras and phosphatidylinositol-3-kinase (PI3K)/Akt pathways through downstream signaling.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Sydney Medical School, Faculty of Medicine & Health, University of Sydney, Sydney, Australia.
Aim: SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial examined the efficacy and safety of canagliflozin according to age.
Methods: Pooled individual participant data from the CANVAS Program (n = 10 142) and CREDENCE trial (n = 4401) were analysed by baseline age (<65 years, 65 to <75 years, and ≥75 years).
Clin Kidney J
January 2025
MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
Background: The serum calcification propensity test (or T50 test) might become a standard tool for the assessment of vascular calcification risk and T50 might be a valuable biomarker in clinical trials of treatments intended to slow the progression of vascular calcification. Literature data suggest that non-calcium-containing phosphate binders can influence T50 in chronic dialysed patients. However, it is not clear whether similar interventions are effective in patients at earlier stages of chronic kidney disease (CKD).
View Article and Find Full Text PDFClin Kidney J
January 2025
Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France.
Background: We sought to comprehensively describe drug-related components associated with acute kidney injury (AKI) in patients with chronic kidney disease (CKD), describing the incidence of drug-related AKI, the proportion of preventable AKI, identified the various drugs potentially associated with it, explored the risk factors, and assessed the 1-year incidences of the recurrence of drug-related AKI, kidney failure, and death.
Methods: CKD-REIN is a French national prospective cohort of 3033 nephrology outpatients with a confirmed diagnosis of CKD (eGFR <60 ml/min/1.73 m²).
Electrolyte Blood Press
December 2024
Department of Internal Medicine, Chung-Ang University, Seoul, Republic of Korea.
Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD). Recent advancements highlight the role of finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), in DKD management. Studies like FIDELIO-DKD, FIGARO-DKD, and FIDELITY have demonstrated finerenone's efficacy in reducing CKD progression and cardiovascular risks in DKD patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!